Back to Browse Journals » Infection and Drug Resistance » Volume 5

Clinical update on linezolid in the treatment of Gram-positive bacterial infections

Authors Ager S, Gould K

Published Date June 2012 Volume 2012:5 Pages 87—102

DOI http://dx.doi.org/10.2147/IDR.S25890

Received 13 April 2012, Accepted 20 April 2012, Published 25 June 2012

Sally Ager, Kate Gould

Department of Microbiology, Newcastle upon Tyne Hospitals Trust, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK


Abstract: Gram-positive pathogens are a significant cause of morbidity and mortality in both community and health care settings. Glycopeptides have traditionally been the antibiotics of choice for multiresistant Gram-positive pathogens but there are problems with their use, including the emergence of glycopeptide-resistant strains, tissue penetration, and achieving and monitoring adequate serum levels. Newer antibiotics such as linezolid, a synthetic oxazolidinone, are available for the treatment of resistant Gram-positive bacteria. Linezolid is active against a wide range of Gram-positive bacteria and has been generally available for the treatment of Gram-positive infections since 2000. There are potential problems with linezolid use, including its bacteriostatic action and the relatively high incidence of reported adverse effects, particularly with long-term use. Long-term use may also be complicated by the development of resistance. However, linezolid has been shown to be clinically useful in the treatment of several serious infections where traditionally bacteriocidal agents have been required and many of its adverse effects are reversible on cessation. It has also been shown to be a cost-effective treatment option in several studies, with its high oral bioavailability allowing an early change from intravenous to oral formulations with consequent earlier patient discharge and lower inpatient costs.

Keywords: linezolid, oxazolidinone, multi-resistant, gram-positive, MRSA, VRE, cost-benefit

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study

Narayanan S, Guyatt V, Franceschetti A, Hautamaki EL

Psoriasis: Targets and Therapy 2015, 5:1-7

Published Date: 23 December 2014

Lumbosacral plexus delineation, dose distribution, and its correlation with radiation-induced lumbosacral plexopathy in cervical cancer patients

Tunio M, Al Asiri M, Bayoumi Y, Abdullah O Balbaid A, AlHameed M, Gabriela SL, Amir O Ali A

OncoTargets and Therapy 2015, 8:21-27

Published Date: 23 December 2014

Proposed criteria for schizophrenia remission

AlAqeel B

Neuropsychiatric Disease and Treatment 2014, 10:619-623

Published Date: 16 April 2014

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Effects of Arthro-7® in relieving symptoms of osteoarthritis with mild to moderate arthralgia [Corrigendum]

Xie Q, Zhou T, Yen L, Shariff M, Nguyen T, Kami K, Gu P, Liang L, Rao J, Shi R

Nutrition and Dietary Supplements 2013, 5:7-8

Published Date: 16 May 2013

Relationship between interblink interval and dopamine

Lemon TI, Shah RD

Clinical Ophthalmology 2013, 7:793-794

Published Date: 29 April 2013

Blood–brain barrier: a real obstacle for therapeutics

Shiekh FA

International Journal of Nanomedicine 2012, 7:4065-4067

Published Date: 27 July 2012